FindTrial
Sign In

INCMGA00012

DRUG7 trials

Sponsors

Incyte Corporation, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Providence Health & Services, Asan Medical Center

Conditions

Advanced Solid TumorsBladder CancerCancer of the Head and NeckCastration Resistant Prostate CancerColorectal CancerEsophageal CancerGastric/ Gastroesophageal JunctionGlioblastoma

Phase 1

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
TerminatedNCT03522142
Incyte CorporationAdvanced Solid Tumors
Start: 2018-08-27End: 2025-09-10Updated: 2025-10-09
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
RecruitingNCT04470024
Providence Health & ServicesCancer of the Head and Neck
Start: 2021-08-05End: 2027-12-31Target: 56Updated: 2025-07-10
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
CompletedNCT04580485
Incyte CorporationBladder Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer +8
Start: 2021-02-03End: 2024-01-22Updated: 2025-07-11

Phase 2

Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
Active, not recruitingNCT04225039
University of PennsylvaniaGlioblastoma
Start: 2020-06-23End: 2029-04-30Updated: 2025-08-15
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
Active, not recruitingNCT04438824
Memorial Sloan Kettering Cancer CenterWell-differentiated/Dedifferentiated Liposarcoma
Start: 2020-06-17End: 2026-06-30Updated: 2025-10-14
PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy
Active, not recruitingNCT04494009
Asan Medical CenterEsophageal Cancer
Start: 2020-09-07End: 2026-12-31Target: 110Updated: 2025-04-20
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)
RecruitingNCT04968106
Institut BergoniéResectable Sarcoma
Start: 2022-12-07End: 2027-10-31Target: 66Updated: 2025-08-13

Related Papers

Predictive value of tumor microenvironment on pathologic response to neoadjuvant chemotherapy in patients with undifferentiated pleomorphic sarcomas.
2024-10-237 citations
Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trial
Cancer Research2024-04-053 citations
680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma
Regular and Young Investigator Award Abstracts2023-10-31
PD1 inhibition and GITR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study.
Journal of Clinical Oncology2023-06-017 citations
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.
Journal of Clinical Oncology2023-06-012 citations
Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
Cancer Research2023-04-14
176P Phase I study of INCB106385 alone or in combination with immunotherapy in advanced solid tumors
Immuno-Oncology Technology2022-12-01
Abstract CT502: Preliminary immunological monitoring of first-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
Cancer Research2022-06-15
443 An immunotherapy trio in advanced HNSCC for coordinated B and T cell antigen response
Regular and Young Investigator Award Abstracts2020-11-01